Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “cMET-dysregulated Advanced Solid Tumors”

3 trials

Showing 3 of 3 results

Early research (Phase 1)Study completedNCT02925104
What this trial is testing

A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.

Who this might be right for
cMET Dysegulation Advanced Solid Tumors
Novartis Pharmaceuticals 36
Early research (Phase 1)Study completedNCT02520752
What this trial is testing

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

Who this might be right for
cMET-dysregulated Advanced Solid Tumors
Novartis Pharmaceuticals 37
Early research (Phase 1)Study completedNCT02626234
What this trial is testing

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

Who this might be right for
cMET-dysregulated Advanced Solid Tumors
Novartis Pharmaceuticals 32

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation